FDA grants IND clearance for Innate Pharma's solid tumour trial [Yahoo! Finance]
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: Yahoo! Finance
It will be conducted in two parts: part one dose escalation and part two dose optimisation. The trial aims to evaluate the tolerability, safety and initial efficacy of IPH4502 when administered as a single agent. Patients with advanced solid tumours known to express Nectin-4 will be enrolled in the study. These include, but are not limited to, people with urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, and colorectal cancers. Nectin-4 is a cell membrane adhesion protein that is overexpressed in several types of solid tumours such as urothelial, breast, oesophageal, lung, ovarian, and pancreatic cancers. It is notably less expressed in normal tissues, making it a promising target for cancer therapy. IPH4502 showed significant anti-tumour efficacy both in vitro and in vivo in non-clinical models. Innate Pharma chief medical officer Dr Sonia Quaratino said: “We are thrilled to advance the IPH4502 programme, and the IND application acceptance is an impo
Show less
Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid TumorsBusiness Wire
- Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.MarketBeat
- Innate Pharma Reports First Half 2024 Business Update and Financial ResultsBusiness Wire